Precision BioSciences, Inc. (DTIL)
| Market Cap | 215.20M +299.2% |
| Revenue (ttm) | 45.07M -11.9% |
| Net Income | -43.60M |
| EPS | -2.62 |
| Shares Out | 25.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 357,357 |
| Open | 8.09 |
| Previous Close | 8.20 |
| Day's Range | 7.93 - 8.59 |
| 52-Week Range | 3.53 - 8.82 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 45.00 (+439.57%) |
| Earnings Date | May 5, 2026 |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price target is $45.0, which is an increase of 439.57% from the latest price.
News
Precision BioSciences sees cash runway through 2028
As of March 31, 2026, Precision had approximately $125.8 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, continued fiscal and opera...
Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year
Reports Q1 revenue $10.8M, consensus $4.05M. “During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts…
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences activates first clinical trial site for PBGENE-DMD
Precision BioSciences (DTIL) announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene e...
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces oral presentation at ASGCT 2026
Precision BioSciences (DTIL) announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy, ASGCT, 2026…
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces grant of inducement awards
Precision BioSciences (DTIL) Board of Directors approved the grant of an inducement award of 7,094 restricted stock units to a new employee under the Precision BioSciences, Inc. 2021 Employment Induce...
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences assumed with a Buy at JonesResearch
JonesResearch assumed coverage of Precision BioSciences (DTIL) with a Buy rating and $30 price target The firm views the company as an “underappreciated gene editing story.” The price target is…
Precision BioSciences receives CTA approval to expand Eliminate-B trial
Precision BioSciences (DTIL) announced that it has received Clinical Trial Application, CTA, approval to expand the ongoing global Eliminate-B clinical trial of PBGENE-HBV. The regulatory authorizatio...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference
ARCUS gene editing platform underpins two lead programs: PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy. Early clinical and preclinical data show promising efficacy and safety, with key data readouts expected in 2026 and a strong cash runway through 2028.
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences reports Q4 EPS $1.05, consensus (64c)
Reports Q4 revenue $34.2M, consensus $9.07M. The increase of $33.6M in revenue during the quarter ended December 31, 2025 was primarily the result of recognizing $26.2M in revenue under the…
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision receives two notices of allowance from USPTO for PBGENE-HBV
Precision BioSciences (DTIL) announced that it has received two notices of allowance from the U.S. Patent and Trademark Office, or USPTO, for patent applications relating to the company’s PBGENE-HBV p...
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences presents new PBGENE-DMD data at conference
Precision BioSciences (DTIL) announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at...
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces fast track designation for PBGENE-DMD
Precision BioSciences (DTIL) announced that the FDA has granted fast track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy. The company also announced that it will host a…
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...